ILK and hepatocellular carcinoma: Consistent with a role for ILK in mediating EGFR tyrosine kinase inhibitor (TKI) resistance, xenograft models of EGFR inhibitor-resistant human hepatocellular carcinoma cell lines found that inhibiting ILK activity increased the sensitivity of cells to EGFR inhibition41.